Vero Combines Stanford's Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive Health
Vero, a predictive health company on a mission to end age-related chronic disease, today announced it is adding cellular resolution to its OrganAge™ platform with an exclusive consumer license to Stanford’s proteomic Cell Clock technology. Developed in the laboratory of Vero co-founder Dr. Tony Wyss-Coray, Cell Clocks measure biological aging across specific cell types, providing a deeper view into the drivers of organ aging and disease risk. By combining organ and cellular aging signals, Vero moves biological aging beyond a single score toward a clinically actionable tool that helps identify where aging is occurring, explain the biology behind it, and guide more precisely targeted interventions.
Creator-First, Ad-Free Social Membership Network VERO Launches VERO100
VERO, the first and only ad-free social membership network with nearly 7M members, yesterday announced the launch of VERO100, a groundbreaking initiative empowering creators with co-ownership of the platform.
Social Network VERO Acquires Regulated Stock Exchange
VERO, the ad-free social network with over 6.5 million registered members, announced its acquisition of the Tokenise Stock Exchange International Ltd, the world’s first regulated stock exchange for tokenised securities. Founded in 2018, Tokenise has developed technology and obtained licenses to fractionalise ownership of various asset classes within a regulated trading environment.
